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shis review covers the period July 2003 to June 2004 with
hree exceptions.
ORTIC STENOSIS
dditional evidence of atherosclerosis and inflammation
n aortic valve (AV) stenosis. Calcified stenotic AV were
hown to have a prevalence of calcium nodules (Fig. 1)
urrounded by markers for inflammation and neoangiogen-
sis that were not present in control valves. The presence of
ctive inflammation correlated with an abundance of thin
eovessels (p  0.01) and heat shock protein (hsp)60 gene
xpression (p  0.04). Neoangiogenesis correlated with
nflammation (p  0.04), calcium (p  0.01), and hsp60
ene expression (p  0.04). These findings “indicate an
ctive immuno-mediated process in the final phase of the
isease” (1).
The genotype distribution of patients with aortic stenosis
AS) differed significantly compared with patients without AS
p 0.03), with increasing prevalence of the apolipoprotein E
llele in those with AS (p  0.01). In multivariate analysis,
ncreasing age and apolipoprotein E allele were significant
ndependent predictors of AS (p  0.046) (2).
Twenty patients with calcific AS had elevated levels
f C-reactive protein compared with control subjects
p  0.013) (3).
Calcified AV stenosis compared with control valves
howed an increase of messenger ribonucleic acid expression
nd activation of matrix metalloproteinases, which may be
he result of insufficient inhibition of endogenous specific
issue inhibitors (4).
chocardiography is superior to electron beam computed
omography (EBCT) for AV calcium. Of 327 subjects in
he Framingham Heart Study, 14% had AV calcium depos-
ts detected by EBCT. Compared with echocardiography,
he AV could not be adequately scanned by EBCT in 18
ubjects (6%), and the sensitivity and specificity of EBCT
or the detection of “degenerative” AV disease were 24%
nd 94%, respectively (5).
iagnostic techniques. MULTISLICE COMPUTED TOMOG-
APHY (CT). Three-dimensional aortic valve calcification
olume showed a close non-linear relationship to echocar-
iographic parameters of severity of AS (6).
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omparison of cardiac magnetic resonance imaging to echo-
ardiography/Doppler (7) revealed that the r value for
elocity time interval was 0.96 and for aortic valve area
AVA) was 0.83. Comparison for AVA showed that the
ethods agreed, exhibiting a mean difference of zero.
Comment: The clinical value of CT and cardiac magnetic
esonance imaging were not studied. At present, for clinical
ractice the two techniques are not comparable to echocar-
iography/Doppler.
mportance of natriuretic peptides (NPs) in patients with
S. B-type natriuretic peptide (BNP), N-terminal BNP
NtBNP), and N-terminal atrial natriuretic peptide
NtANP) were determined in 130 patients with severe AS
ho were followed for 377  150 days (8). The NP
ncreased with increasing New York Heart Association
NYHA) functional classes and decreasing left ventricular
jection fraction (LVEF). Asymptomatic patients who later
ecame symptomatic had higher levels of BNP and NtBNP
t baseline.
n patients presenting with chest pain, AV sclerosis was
ot a predictor of cardiac death and myocardial infarc-
ion (MI). Of patients presenting in the emergency depart-
ent, AV sclerosis was identified in 203 of 405 patients
49%) (9). On multivariate analysis, independent predictors
f cardiac death or MI at one year were coronary artery
isease (p  0.003), MI at index admission (p  0.008),
scending terciles of C-reactive protein (p  0.001), con-
estive heart failure (HF) (p  0.02), and age (p  0.04).
s “contractile reserve” of value in patients with low gradi-
nt AS? Yes and no. This prospective study enrolled 136
atients with severe AS, AVA 0.7 cm2, and LVEF 0.31. Left
entricular (LV) “contractile reserve” was defined as an increase
f LV stroke volume (obtained from echocardiography/
oppler) of20% with intravenous dobutamine infused up to
maximal dose of 20 g/kg/min (10). Group I was composed
f 92 patients who had “contractile reserve,” and Group II was
omposed of 44 who had no “contractile reserve.” Decisions for
urgery were made by individual clinicians. At three years,
atients in both groups who had surgery had a better survival
han those treated medically. An improvement in functional
lass occurred in 84% of Group I patients and in 45% of Group
I patients (p 0.002); medical treatment was “equally poor in
oth groups.”
Comment: Contractility was not determined. In both
ubgroups, survival and functional outcomes were better
ith surgery than no surgery; not a helpful study. Assess-
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Year in Valvular Heart Disease January 4, 2005:111–22ent of myocardial viability may be of value in Group II
atients (see “Mitral Regurgitation”).
ORTIC REGURGITATION (AR)
Ps are elevated in patients with AR. Compared with
ontrol subjects, NPs were elevated in asymptomatic pa-
ients with AR (p 0.05); symptomatic patients had higher
evels (11).
atients with severe AR may have right ventricular (RV)
iastolic dysfunction. Forty consecutive patients with AR,
VEF 0.55, LV end-diastolic pressure 15 mm Hg, RV
ystolic pressure 30 mm Hg, and normal coronary arteries
ad evidence of abnormal RV relaxation and filling as
ssessed by echocardiography/Doppler (12). There was no
escription of the septal movement or of the findings on
linical examination of the patient.
Comment: This is probably the Bernheim syndrome/effect
rst described in 1910 (13). Paul Wood stated that it was a
esult of LV dilation, and also of rapid dilation of the LV in
arly diastole (e.g., from left-sided valve regurgitation) so
hat the septum bulges into the RV and interferes with
roper filling of the RV; therefore, the RV is small and the
ight atrium is large (14). Clinical examination shows
levated jugular venous pressure, absence of RV heave, and
ecause there is no increase in pulmonary vascular resistance
he intensity of P2 is normal.
V repair with good results is feasible in selected pa-
ients. Between 1986 and 2001, 1,410 patients had surgery
or severe AR of whom 160 (11%) had valve repair (15).
here was one operative death (0.6%), and two patients
equired early re-repair; at a mean interval of 2.8 years 10%
ad re-operation. At seven years, survival was 89% and
e-operation on the AV was 15%.
ICUSPID AORTIC VALVE
revalence of bicuspid aortic valve (BAV) is high. In a
igure 1. Calcific aortic stenosis valve leaflet showing areas with ossifica-
ion and bone marrow formation. (From Mazzone et al. [1]).rospective study of 817 children (400 males, 417 fe- rales, age 10 years) attending primary school in a valley
ith 41,432 inhabitants (16), echocardiography of the
hildren showed BAV in 0.5%; prevalence in males versus
emales was 0.75% versus 0.24%. The dimensions of the
ortic root in patients with tricuspid aortic valve (TAV)
ersus BAV at the level of the annulus were 18.4  2.6
m versus 20.5  2.6 mm, at the sinuses of Valsalva were
2.2  2.4 versus 25.7  2.0 (p  0.02), and in the
scending aorta were 19.7  2.3 versus 22.2  4.4 (p 
.001).
AV is heritable. Of 309 probands and relatives, echocar-
iography showed BAV in 74 (prevalence 24% and a
eritability [h2] of 89%); BAV and/or other cardiovascular
alformation in 97 (prevalence 31%, h2 75%) (17).
bnormalities in aneurysmal tissue of BAV and Marfan
yndrome. Marfan syndrome is known to be a genetic
isorder caused by a mutation in the fibrillin gene (18).
istology showed areas of cystic medial necrosis without
nflammatory infiltrate in tissues of both groups. Immuno-
istochemical study of cultured BAV and of Marfan syn-
rome vascular smooth muscle cell (VSMC) showed intra-
ellular accumulation and reduction of extracellular
istribution of fibrillin, fibronectin, and tenascin (18). The
SMC of both groups showed no increase in expression of
brillin, fibronectin, or tenascin, and an increased expres-
ion of matrix metalloproteinase-2 in Marfan syndrome
Fig. 2). There was a four-fold increase in loss of cultured
SMC incubated in serum-free medium for 24 h of 32 
% in BAV and of 27  8% in Marfan syndrome versus in
ontrols of 7  5%, p  0.05. Thus, the findings in both
roups are similar. The authors concluded the findings
suggest the presence of a fundamental cellular abnormality
n BAV thoracic aorta.” (Also see information on mitral
alve prolapse under “Mitral Regurgitation”).
Two other studies showed reduction of fibrillin and an
ncrease of matrix metalloproteinase-2 in the walls of
neurysms associated with BAV (19,20).
ortic dilation in BAV. In younger people, aortic diameters
ssessed by echocardiography were greater in BAV (n  10)
han in TAV (n 18) (Table 1); 60% of those with BAV had
1 aortic diameter measurement in the 95th age-adjusted
ercentile (21).
rogression of aortic dilation in adults with BAV. Sixty-
ight patients, mean age 44 years, with BAV had an average
ollow-up of 47 months with at least two echocardiographic
tudies 12 months apart (22). Aortic diameters increased
mean; 95% confidence intervals) at the sinus of Valsalva
1.9 mm; 1.3 to 2.5), at the sinotubular junction (1.6 mm;
.8 to 2.3), and at the proximal ascending aorta (2.7 mm;
.9 to 3.6). Average of mean aortic gradient increased from
7.6 to 25.7 mm (p  0.001), and the degree of AR
ncreased in 17 patients (25%). Progression of aortic diam-
ter dilation occurred irrespective of baseline BAV function.
The failure of BAV may relate to the different way it
erforms. Cryopreserved and then thawed human aortic
oots containing BAV were studied in a left heart simulator
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January 4, 2005:111–22 Year in Valvular Heart Diseasesing intravascular ultrasound and high-speed (500
rames/s) cinematography (23). The function of the clini-
ally “normal” BAV was characterized by: 1) excessive
olding and creasing, which (unlike in the TAV) persisted
hroughout the cardiac cycle; 2) extended areas of leaflet
ontact; 3) asymmetrical flow patterns and turbulence which
ubject the BAV to abnormal stresses; and 4) significant
orphologic stenosis.
oes aortic valve replacement (AVR) stabilize the as-
ending aortic dilation? Yes and no. YES. Follow-up
30.0  23.4 months) in 185 patients undergoing AVR
howed no increase in ascending aorta dimension (24), and
rogressive aortic dilation occurred in only 9.3%. No patient
ith baseline aortic dilation of 3.5 to 5.3 cm dilated beyond
.5 cm.
Comment:Only 13 of 185 patients (7%) had “congenitally
bnormal valve,” presumably BAV.
O. In a study of 13 patients with BAV, and 14 with TAV
efore and after AVR, and of 18 BAV without AVR (25),
he aortic dilation in BAV patients tended to be faster than
ith TAV; however, a statistically significant difference was
ound only at the proximal aorta (0.18  0.08 vs. 0.08 
.08 mm/m2 per year; p  0.03). Patients with BAV
howed similar progressive dilation with or without AVR.
igure 2. Cultured control vascular smooth muscle cells (VSMC) (A to
mmunohistochemistry using antibodies against fibrillin (A, D, G), fibrone
et al. [18]).
able 1. Size of Ascending Aorta in BAV and TAV
Level of Ascending Aorta BAV TAV
ortic sinuses (mm) 41.1  8.1 33.8  3.3
ino-tubular junction (mm) 39.0 7.8 31.1  3.8
scending aorta (mm) 42.8 7.1 33.7  4.3w
 0.005 for all three values. From Morgan-Hughes GJ et al. (21).
BAV  bicuspid aortic valve; TAV  tricuspid aortic valve.atients in the AR dominant subgroup showed a tendency
f more progressive dilation (p  NS). Patients with TAV
id not show further dilation after AVR.
Comment: This study included small numbers of patients.
fter AVR, in patients with BAV the ascending aortic
ilation is likely to be progressive but not in those with
AV.
ITRAL STENOSIS
on-invasive assessment of mitral valve area (MVA) is
est by real-time three-dimensional echocardiography
RT3D). The MVA by pressure half time, two-dimensional
chocardiography, proximal iso-velocity surface area, and
T3D were compared with MVA obtained within 24 h by
sing the Gorlin formula (simultaneous LV-left atrial pressures
nd cardiac output by thermodilution) in 80 patients (26).
ompared with all other echocardiography/Doppler methods,
VA by RT3D had the best agreement with MVA obtained
y the Gorlin formula (average difference with both methods
as 0.08 cm2, and the range of limits of agreement was0.48
o 0.6). The RT3D showed the best interobserver and intraob-
erver variability with Kappa indexes of 0.84 and 0.96, respec-
ively. The authors concluded that RT3D is “feasible, accurate
nd highly reproducible for assessing MVA” and “has the best
greement with high-quality invasive methods.”
obutamine stress echo in predicting clinical events. Dobu-
amine stress echo (DSE) was performed in 53 patients
ge 37.4  11.3 years. During follow-up (60.5  11.0
onths), 29 patients presented with clinical events; the
est performance of DSE for prediction of clinical events
arfan syndrome (D to F), and bicuspid aortic valve (BAV) (G to I).
, E, H), and tenascin (C, F, I).Magnification 250. (From NataatmadjaC), Mas at a cutoff value of 18 mm Hg DSE-mean gradient
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Year in Valvular Heart Disease January 4, 2005:111–22hich had a sensitivity of 90%, specificity of 87%, and
ccuracy of 90%. The authors stated the addition of DSE
o “conventional cardiology work-up would allow a 17%
ncrement for detection of high-risk patients in the entire
opulation and 40% increment in patients with presumed
oderate disease.” (27)
Comment: An accompanying editorial stated that the role
f DSE is of value “in selecting those patients with
ymptoms out of proportion to the severity of their calcu-
ated mitral valve area who will most probably benefit from
n intervention that may be either medical or invasive.” (28)
lder patients have less good outcome with catheter
alloon commissurotomy. Older patients had more co-
orbid cardiac conditions; at five years, they had higher
ortality and fewer patients were in NYHA functional
lasses I and II (Table 2). The echocardiographic score did
ot correlate well with age (29).
uccessful catheter balloon commissurotomy does not
revent development of subsequent atrial fibrillation. Of
23 consecutive patients with catheter balloon commissurot-
my, 181 had no history of atrial arrhythmias. Atrial fibrilla-
ion developed in 37 (20%) patients (30). Patients who devel-
ped atrial fibrillation were older (p  0.001), had a higher
cho score, and had a larger left atrial diameter (p  0.004).
ITRAL REGURGITATION
asic abnormalities of mitral valve (MV) leaflets and
hordae in mitral valve prolapse (MVP). It has been
nown that the myxomatous degeneration seen in MVP has
ndings on gross and histologic examination that are
dentical to those seen in Marfan syndrome. Marfan syn-
rome results from mutation in the gene that codes for
xtracellular protein fibrillin, but the fibrillin in MVP is not
nown (31). The leaflets of MV in areas of myxoid
egeneration, examined by immunohistochemical staining,
howed a more diffuse, weaker, and non-laminar pattern for
brillin (31) (Fig. 3). Similar, but less severe abnormality of
lastin, collagen I, and collagen III were also present. The
bnormal fibrillin and altered protein matrix architecture
ay contribute to the development of myxomatous degen-
ration (also see section on BAV).
The MV leaflets and chordae in MVP had 3% to 9%
able 2. Patient Outcomes After CBC for MS
Age
(yrs)
Patients
(n)
At 5 Yrs
NYHA
Functional
Class I/II (%)
Mortality
(%)
40 19 87 0
0–54 101 63 5
5–69 173 36 31
70 112 19 59
rom Shaw TRD et al. (29).
CBC catheter balloon commissurotomy; MS mitral stenosis; NYHA New
ork Heart Association.igher water contents and 30% to 150% higher concentra- dions of glycosaminoglycans than normals when expressed
n terms of dry weight (p  0.005) (32). There are lower
ollagen concentrations in the leaflets compared with nor-
als (p  0.002). The biochemically measurable effects
ere more pronounced in chordae than in leaflets.
ifferent mechanisms responsible for exercise-induced
ncrease of mitral regurgitation (MR). Seventy patients,
n chronic post-MI phase and LVEF 0.45, showed a
ide range of exercise-induced effective regurgitant ori-
ce (ERO) that was not related to the degree of MR at
est (r  0.20). On exercise, the independent predictors
f ERO were changes in mitral deformation (i.e., differ-
nces in systolic mitral tenting area, systolic annular area,
nd coaptation height; p  0.0001) and wall motion
core in anterior and inferior MI groups. Larger changes
n ERO in both infarct groups were associated with
osterior displacement of the papillary muscles. Apical
isplacement of the mitral leaflets was important in
atients with anterior MI. A decrease in ERO was seen
n patients with inferior MI who had improvement in
all motion score. The changes in ERO “are related to
hose in LV remodeling and in mitral deformation but
ot those in global LV function.” (33)
Comment: Echocardiography/Doppler must be performed
igure 3. Immunohistochemical staining of mitral valve leaflet from a
itral valve prolapse syndrome patient with severe myxoid degeneration.
mmunohistochemical staining for (A) collagen I, (B) collagen III, (C)
brillin, and (D) elastin exhibit weak, diffuse, and disorganized staining
atterns with lack of zonal restriction that is seen in normal valves (a 
trial surface; v  ventricular surface). (From Nasuti JF et al. [31]).uring, and not after, peak exercise.
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January 4, 2005:111–22 Year in Valvular Heart Diseasencreased extravascular norepinephrine (NE2) release
ate. The NE2 increase after mitral valve repair (MVrep) (34)
as directly proportional to the changes in LV end-systolic
imension (r  0.01, p  0.001) and inversely related to the
hanges in LV fractional shortening (r  0.82, p  0.001)
nd LVEF (r  0.78, p  0.001).
mportance of magnitude of viable myocardium in de-
ermining postoperative survival. Fifty-four patients with
VEF of 0.27  0.09 had viable myocardium identified by
ositron emission tomography (35). After MVrep, those
ith 5 segments of viable myocardium had a higher
ix-month mortality than those with 5 segments of viable
yocardium, 43% versus 3.6% (p  0.01).
RICUSPID VALVE DISEASE
esults of tricuspid valve replacement with mechanical and
ioprosthetic prosthetic heart valve (PHV) are similar. Data
rom 11 studies with 646 mechanical and 514 biologic
alves, median age 50 years, were pooled (36). The hospital
ortality for tricuspid valve replacement was 19%. There
as no significant difference in late survival between the two
ypes of prosthesis; mortality (excluding hospital mortality)
t 1, 5, 10, and 15 years was approximately 14%, 26%, 40%,
nd 52%, respectively. There was a large variability in
omplication rates between the studies. There was no
ignificant difference between valve types with regard to
hrombosis or structural valve deterioration (SVD).
NFECTIVE ENDOCARDITIS (IE)
ntibiotic prophylaxis reduces the incidence of bactere-
ia. In this double blind, randomized, placebo-controlled
rial, children were assigned to the American Heart
ssociation-recommended dose of amoxicillin or to a placebo
37). Aerobic and anaerobic blood cultures were drawn at eight
pecific times before, during, and after the procedure in 100
hildren (mean age 3.5 years). At least one of the eight cultures
as positive in the placebo group in 84% versus 33% (p 
.001) in the amoxicillin group. Bacteremia occurrence rates
ere lower in the amoxicillin group (Table 3).
Comment: This is an early step in documenting the
linical benefit of antibiotic prophylaxis.
levated procalcitonin level for early diagnosis. Procal-
itonin levels were higher in patients with IE than in those
ith other final diagnoses (p  0.001). At a cutoff value of
.3 ng/ml for diagnosis of IE, the sensitivity, specificity,
egative and positive predictive values were 81%, 85%, 92%,
able 3. Incidence of Bacteremia in the Placebo and
moxicillin Groups
Placebo Amoxicillin
p
Value
fter intubation 18% 4% 0.05
ental restoration and cleaning 20% 6% 0.07
.5 min after dental extraction 76% 15% 0.001nd 72%, respectively (38). tarly clinical predictors of in-hospital death. In 267
onsecutive patients, the in-hospital mortality was 20%.
ighty-two percent of patients had native valve IE. Inde-
endent predictors of death by logistic regression analysis
ere embolic event, diabetes mellitus, Staphylococcus aureus,
nd APACHE II score. APACHE II includes “acute
hysiology,” age, and chronic health evaluation (39).
redictors for “major” embolic event. Overall, 75 symp-
omatic embolic events occurred in 43 of 94 patients (46%)
40). Seventy percent of patients had native valve IE. By
ultivariate logistic regression analysis, predictors of em-
olic event were young age (p  0.006), vegetation size
p  0.045), and C-reactive protein (p  0.028).
Comment: A good transesophageal echocardiogram (TEE)
s essential for clinical practice. It is of great value for the
iagnosis of IE; the additional information it provides (e.g.,
egetation size, abscess) is also of value in clinical decision-
aking. It must be performed urgently in such patients.
spirin does not reduce risk of an embolic event. In a
ulticenter double-blinded, placebo-controlled, random-
zed trial of aspirin versus placebo, the embolism rate was
8.3% versus 20.0% (p  0.29) and the bleeding rate was
8.8% versus 14.5% (p  0.075) (41).
alve surgery reduces six-month mortality. Of 513 adults
ith complicated, left-sided native IE treated with antibi-
tics, 45% underwent valve surgery and 55% received
edical therapy alone. The six-month mortality in those
ith valve surgery versus no valve surgery was 16% versus
3%, p  001 (42). Patients with moderate to severe heart
ailure (HF) showed the greatest reduction in mortality with
urgery (14% vs. 51%, p 0.001). Most of the deaths in the
o surgery group occurred in the first two weeks.
VREP WAS FEASIBLE IN 63 OF 78 (81%) PATIENTS. Early
omplications were: two deaths (3.2%) and two re-
perations, of which one was for severe MR and one for
ubsequent aortic IE. For all 78 patients, the seven-year
urvival was 78  6%; multivariate predictors of event-free
urvival were hypertension (p  0.006) and intervention for
cute endocarditis (p  0.020). Five-year survival after
Vrep for acute endocarditis was 96  4% and for healed
ndocarditis was 91  5% (43).
ERCUTANEOUS VALVE AND RELATED SURGICAL
ROCEDURES
ercutaneous pulmonary valve (PV) replacement. Since
001, 23 of 24 patients have had successful PV replacement
hen the RV outflow tract did not exceed the maximum
iameter of 22 mm. A larger stent developed for those with
arger RV outflow tract was successfully implanted in 8 of 10
atients (44).
ercutaneous AV replacement. A PHV was successfully
mplanted in the subcoronary position in the first five of six
nonsurgical patients” with “end-stage” calcific AS; the sixth
atient died shortly thereafter because the device was ejected
o the ascending aorta. In the five patients, the AVA
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Year in Valvular Heart Disease January 4, 2005:111–22ncreased from 0.49  0.08 to 1.66  0.13 cm2, LVEF
ncreased from 24  9.5 to 41  12%; in two patients
R2 increased to 3; three of five patients died of
on-cardiac causes at two, four, and eight weeks (45).
ercutaneous mitral annular reduction for MR. In nine
dult sheep, HF and MR were produced by rapid ventric-
lar pacing. A mitral annular constraint device (Fig. 4) was
mplanted through the right internal jugular vein in the
oronary sinus and the great cardiac vein to create a
hort-term stable reduction (24.9  2.5%) in the mitral
nnular septal-lateral dimensions (46). The MR, quanti-
ated echocardiographically and expressed as ratio of left
trial area (MR/LAA), was reduced from 42  6% to 4 
%. Mean pulmonary artery wedge pressure fell from 26 
to 18 3 mmHg (p 0.01) and cardiac output increased
rom 3.4  0.3 to 4.3  0.4 l/min (p  0.01).
ercutaneous endovascular end-to-edge MVrep. This
rocedure was successfully performed in 12 of 14 adult pigs
Fig. 5); in 2 animals the clip released from the anterior
eaflet. In the remaining 12 animals, the clip successfully
pproximated the middle scallops of the anterior and pos-
erior leaflets to produce double orifice mitral valves (47),
hich is similar to the Alfieri repair in humans.
urgical edge-to-edge MVrep. Alfieri presented data on
1 patients who underwent this procedure without annulo-
lasty from 1993 to 2001 (48). There were three hospital
eaths and four late deaths. At four years, the survival was
5  6.7%; 61 patients were in NYHA functional classes I
r II, 9 were in classes III or IV; 9 patients required
e-operation (freedom from re-operation was 89  3.9%).
nly 1 of 42 patients required re-operation when annular
alcification, rheumatic disease, or rescue procedure were
ot present as risk factors. The authors concluded that
verall results of the edge-to-edge technique are suboptimal
hen annuloplasty is not added to the repair.
A cohort of 224 patients underwent the Alfieri MVrep
igure 4. The position of the mitral annular constraint device in the
oronary sinus and its relation to the posterior aspect of the mitral valve.
lements of the device, including proximal and distal anchors and an
ntervening cable, are depicted. (From Kaye DM et al. [46]).rom 1997 to 2001 of whom 188 (84%) also underwent 7oncomitant ring annuloplasty. Preoperative MR was 4 in
09 patients (50%) and 3 in 65 (30%). Hospital mortality
as 2%. At three months, MR was present in 60% and was
 in 14%, the incidence of which rose “slowly thereafter”
49). The authors concluded: “In ischemic MR, steadily
ncreasing prevalence of moderately severe and severe regur-
itation after edge-to-edge repair suggests other techniques
re needed.”
Comment: Tests for viability were not described in the last
tudy (49) (see another article from the same institution in
he section on MR). Mitral valve repair by percutaneous
echniques is promising but needs further development and
efinement. For MVrep, by percutaneous or surgical tech-
iques, a combination of procedures and appropriate patient
election are likely to be needed.
ROSTHETIC HEART VALVES
echanical PHV. STARR-EDWARDS AND ST. JUDE VALVES
AVE SIMILAR OUTCOMES. A prospective randomized trial
f the Starr-Edwards valve (a model in use since 1965) and
he St. Jude valve (first used in 1977) was performed at St.
homas Hospital, London, United Kingdom (50). For
VR and for mitral valve replacement (MVR) there were
o significant differences in survival, event-free survival, and
ll outcomes (Fig. 6, Table 4). Survival after AVR was
elated to LV function. Only 10% of all the deaths in the
hole trial were related to the PHV. The average reduction
n NYHA functional classes from preoperative levels to five
ears for Starr-Edwards and St. Jude for AVR was 1.4 and
.5, respectively, and for MVR was 1.8 and 1.6, respectively.
Comment: This study is the only randomized trial com-
aring patient outcomes with different mechanical PHVs.
ONG-TERM RISK OF STROKE AND THE BENEFIT OF THE
AZE PROCEDURE AFTER MVR. Of 812 patients (age 18 to
igure 5. (A) Schematic of the endovascular repair system guide catheter
CVRS, E valve) across the atrial septum. The clip delivery system is
ositional through the guide. The clip is in the open position in the left
entricle, ready to be retracted to grasp the mitral leaflets. (B) The distal
nd of the delivery system and the polyester-covered clip shown in the open
osition. (From St. Goar FG et al. [47]).9 years, median 58 years) who underwent MVR with a
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January 4, 2005:111–22 Year in Valvular Heart Diseaseechanical prosthesis, the 15-year survival was 85.4 3.2%
51). Risk factors for late mortality by multivariate analysis
ere preoperative NYHA functional class IV (p  0.0032)
nd age 65 years (p  0.0001). At 15 years, the freedom
rom stroke was 90.7  6.5% in patients with regular
hythm compared with 73.8  6.9% in patients with
hronic atrial fibrillation (p  0.0001). The risk factors for
troke on multivariate analysis were: history of stroke (p 
.0003), chronic atrial fibrillation (p  0.0004), no Maze
rocedure (p 0.03), and year of operation (p 0.05). The
ate incidence of atrial fibrillation was much lower in those
ho had a concomitant Maze procedure (Fig. 7).
NTERNATIONAL NORMALIZED RATIO (INR) SELF-
ANAGEMENT. The Early Self Controlled Anticoagulation
rial II (ESCAT II) (52) randomized multicenter trial began
n 1998 and compared a “conventional” group (INR 2.5 to 4.5)
ith a “low-dose” group (AVR: INR 1.8 to 2.8; MVR/double
alve replacement (DVR) INR 2.5 to 3.5). The INR was
ithin therapeutic range in 74% in the conventional group and
2% in the low-dose group. The linearized thromboembolic
ate was 0.21% per year and for bleeding in the low-dose group
ersus the conventional group was 0.56% versus 0.91% per year
p  NS).
igure 6. Survival after aortic valve replacement (AVR) (left panel) and m
edical mechanical prosthetic heart valve. Dashed lines  St. Jude Med
Table 4. Outcomes at 8 Years After Randomiz
At 8 Years Starr-Edwa
Survival 65  5%
Freedom from thromboembolism 86%
Event-free survival 43%From Murday AJ et al. (50).
AVR  aortic valve replacement; MVR  mitral valve replacemComment: The low-dose group had an INR range almost
dentical to the recommendations in the 1998 American
ollege of Cardiology/American Heart Association Guide-
ines, which were INR 2.0 to 3.0 for AVR and 2.5 to 3.5 for
VR (53).
ioprosthetic PHV. MORE GOOD NEWS ABOUT THE
ARPENTIER-EDWARDS PERICARDIAL VALVE (CE-PV). A
rospective randomized trial compared CE-PV to the
oronto Stentless Porcine Valve (T-SPV). The primary end
oint was regression of LV mass determined by echocardi-
graphy indexed to body surface area (LVMI); the second-
ry outcome was the Duke Activity Status Index (54).
verall LVMI at 12 months for CE-PV and T-SPV was
2.3 g/m2 versus 23.8 g/m2 (p  0.39). The Duke Activity
tatus Index scores improved significantly over time in both
roups (p  0.001); there was no significant difference
etween the two types of PHV (p  0.10). Other findings
re also of interest: Cardiopulmonary bypass times were
onger for the T-SPV versus CE-PV (148.5  30.9 min vs.
18.6  36.3 min, p  0.0001), and also for aortic
ross-clamp times T-SPV versus CE-PV (123.6  24.1
in vs. 95.4  28.6 min, p  0.0001). The AVA improved
ver time in both groups but was not statistically significant
valve replacement (MVR) (right panel) with Starr-Edwards and St. Jude
olid lines  Starr-Edwards. (From Murday AJ et al. [50]).
MVR
St. Jude Starr-Edwards St. Jude
71  4% 54  7% 44  8%
88% 68% 73%
45% 29% 25%ation
AVR
rdsent.
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Year in Valvular Heart Disease January 4, 2005:111–22n the T-SPV (p  0.66), whereas the AVA in the CE-PV
mproved from 3 to 12 months from 1.53  0.45 to 1.91 
.9 cm2 (p  0.005). However, at 12 months the difference
etween the two was not significant: T-SPV versus CE-PV,
.74 versus 1.91 cm2 (p  0.34).
Comment: This study is the only randomized trial com-
aring valve areas of two bioprosthetic valves at 12 months
fter AVR. The stentless valve is more difficult to insert,
hich accounts for the longer bypass and cross-clamp times.
ll readings of echocardiograms were performed at the core
ite by two experienced echocardiographers who were
linded to patient and prosthesis. The manufacturer’s la-
eled valve size was much bigger for the T-SPV (26.3 2.0
m vs. CE-PV 22.9  2.0 mm, p  0.0001). The reason
he AVA at 12 months was not different was because the
ctual manually measured internal diameters before implan-
ation were not significantly different (CE-PV 21.9  2.0
m vs. T-SPV 22.3  2.0 mm, p  0.29). The implication
s to rely on the information of the effective internal
iameter of PHV, and not on the manufacturer’s stated
alve sizes (55). The Magna CE-PV, recently approved by
he Food and Drug Administration, has an even larger
ffective internal diameter for any stated valve size.
V MASS REGRESSION IS SIMILAR FOR THREE DIFFERENT
ALVE SIZES. The LV mass regression was evaluated 12
onths after CE-PV insertion with 19-mm valves in 34
atients, 21-mm valves in 29 patients, and 23-mm valves in 25
atients (56). At follow-up after 2.3 1 years, the AVA index
cm2/m2) in the three groups was 0.74  0.12, 0.82  0.15,
.86 0.13, respectively (p 0.05 for 19 mm vs. 21 mm and
s. 23 mm). The relative LVMI regression (g/m2; mean 
D) in the three groups was20.7 18.9,19.3 17.8, and
21.9  15.7 (p  0.86) (Fig. 8).
Comment: Inserting a small PHV in smaller people will
ave beneficial effects; the AVA index at 6 to 12 months
fter PHV insertion is also an important determinant of
atient outcomes. (Also see the preceding text and valve
rosthesis-patient mismatch).
igure 7. Percent freedom from atrial fibrillation (AF) up to eight years
fter mitral valve replacement (MVR) with Maze operation versus MVR
lone. The MVR was performed using mechanical prosthetic heart valve.
From Bando K et al. [51]).At 10 years, the freedom from SVD for the CE-PV (n  p,021) was 98.5  1% versus 92  2% (p  0.04) for
E-porcine valve (n  518) (57). In patients 70 years of
ge at the time of implantation of CE porcine valve, the rate
f SVD was low at 15 to 18 years (57).
The CE-PV have a lower rate of SVD deterioration than
orcine valves, including the T-SPV and Hancock II valve.
he latter two PHV had SVD rates similar to earlier stented
alves (58).
In an experimental study in rats, PHV were examined 90
ays after implantation (59). The mean calcium content
g/mg dry weight) of CE-PV was 3.30, which was
ignificantly lower than that of another pericardial valve,
itroflow (214.60; p 0.01). The mean calcium content of
he CE-PV was also lower than that of porcine valves, the
edtronic Mosaic (25.37; p  0.02) and the Toronto SPV
244.43; p  0.01) but not that of other CE-porcine valves.
Since 1992, CE-PV and CE-porcine valve are treated
ith XenoLogix (containing alcohol and Tween-80) during
alve preparation. This experimental study provides one
ossible explanation for the lower rate of SVD with
E-PV.
E-OPERATIVE MORTALITY FOR SVD OF PORCINE MITRAL
HV IS LOWER IN THE RECENT ERA. There were 34 deaths
n 463 patients (7.3%) (60). The mortality from 1975 to
986 was 9.8%, from 1987 to 1992 was 10.8%, and from
993 to 2000 was 3.4% (p value for third vs. first time period
as 0.05 and vs. second time period was 0.0005). The
ortality for elective/urgent re-operation was 6% versus
7.8% for emergent (p  0.0009). The mortality for
atients in NYHA functional classes I and II was 0% (0 of
7), III was 5.1% (14 of 273), and IV was 11.7% (20 of 171)
p  0.007). In the third time period, independent predic-
ors of mortality by multivariate regression analysis were age
t implant and at explant.
Comment: In this study there was a small number of
igure 8. Reduction of left ventricular (LV) mass after aortic valve
eplacement (AVR) with use of the Carpentier-Edwards pericardial valve
CE-PV) 19 mm (left panel), 21 mm (middle panel), and 23 mm (right
anel). BSA  body surface area. (Figure was created from data in Tasca
et al. [56]).atients in NYHA functional classes I and II.
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January 4, 2005:111–22 Year in Valvular Heart Diseasearly autograft dysfunction after the Ross principle
peration is not infrequent. Ninety-one patients, age
7  10 years, underwent pulmonary autograft for AVR
nd cryopreserved homograft in the pulmonary position.
ollow-up was 4.0  1.9 years (range 1 to 8 years) (61). At
even years, freedom from aortic dilation was 42  8%,
reedom from regurgitation was 75  8%, and freedom
rom re-operation was 85  10%.
hrombosed PHV. IMPORTANCE OF THROMBUS SIZE DI-
GNOSED BY TEE. From 1985 to 2001, 107 patients (71
emales; age 24 to 86 years) from 14 centers, all of whom
ad good definition of thrombus size by TEE, were iden-
ified (62). The mitral valve was affected in 73.8%, aortic in
2.2%, and tricuspid valve in 14%. A definite mass was seen
n 86.2%; the largest area was 14.7 cm2. The inability to
isualize a mass on an obstructed valve was usually associ-
ted with a small thrombus or pannus affecting the lineage
f prosthesis. Thrombi without significant hemodynamic
bstruction were observed in 14 patients. After thrombo-
ytic therapy, complete hemodynamic success (defined as
eturn of gradient to “normal” levels) was achieved in 76.3%
f the 93 obstructed valves, and partial success was seen in
.6%. Thrombus with a soft mass was associated with a
uccess rate of 91.5%, and a hard mass with a 75% success
ate. A soft mass by TEE was the single best predictor of
uccess (p  0.029). Clinical success (defined as hemody-
amic success without clinical complications) was achieved
n 73.8%; for aortic, mitral, and tricuspid valves the success
ates were 63.6%, 74.6%, and 93.3% (p  NS). In a logistic
egression model, independent predictors of success were
maller thrombus area by TEE and lack of previous history
f stroke (Table 5). Complications occurred in 17.8%
Table 6).
Comment: A good TEE is essential for clinical decision-
aking; it must be performed urgently in such patients
ecause they are at high risk. The method used to calculate
he thrombus area was not described; assuming the shape of
he thrombus is a circle, a thrombus size of 0.8 cm2
alculates to a diameter of 1 cm.
ARLY THROMBOSIS AFTER MITRAL PHV AND OUTCOME
ELATED TO THROMBUS SIZE. A cohort of 680 patients
nderwent TEE on day 9 after mechanical PHV. Early
hrombi were detected in 64 (9.4%) (63). Maximum
hrombus size 5 mm was observed in 29 (45%) patients
Group A) and 5 mm was observed in 35 (55%) patients
Group B). During early follow-up, complications occurred
n 3.4% in Group A versus 22.9% in Group B patients (p 
.027). In the long-term survey, complications occurred in
0.3% Group A patients and 31.4% Group B patients (p 
.04).
Comment: The adequacy of anticoagulant therapy (early
nd late) was not described. Issues that need to be resolved
re: Should all patients have early TEE after MVR, and if
hrombus is found how should it be treated? FHV THROMBOSIS IS ASSOCIATED WITH A HIGH SHORT-
ND LONG-TERM MORTALITY. From 1981 to 2001, 39 of
,924 patients (0.8%) had thrombosis of PHV (64). The
ime from valve replacement to thrombosis was 39  42
onths. Forty-four percent presented in severe HF; 82%
nderwent a surgical procedure (thrombectomy in 47%,
VR in 47%, AVR in 6%). The three-day and total
n-hospital mortality were 25% and 41%, respectively. The
0-year actuarial survival was 46  10%.
Comment: The incidence of PHV thrombosis is low, but
t is potentially a life-threatening complication.
ETECTION OF PHV THROMBOSIS. Fluoroscopy was suc-
essful in the detection of thrombosis of bileaflet valves (65).
ulti-detector-row CT was successful in the detection of
annus formation (66). Using transcranial Doppler ultra-
able 5. Outcome With Thrombolytic Therapy in Patients
ith Thrombosed PHV
Complication
Rate Death
YHA FC I–II
Thrombus 0.8 cm2 0 0
Thrombus 0.8 cm2 41% 0
p value 0.003 —
YHA FC III–IV
Thrombus 0.8 cm2 10.8% 5.4%
Thrombus 0.8 cm2 32.3% 12.9%
p value 0.03 —
hrombus Area
0.8 cm2 6.25% 3.1%
0.8–1.5 cm2 28.6% 3.6%
p value 0.003 —
1.6 cm2 46.7% 20%
p values vs. 0.8 cm2 0.0001 0.016
vs. 0.8–1.50 cm2 — 0.07
isk Factors
Thrombus area 0.8 cm2 34.9% 9.3%
History of stroke 42.3% 11.5%
Both risk factors 78.6% 21.4%
None of the two risk factors 7.7% 3.9%
able constructed from data in the Figures in Tong AT et al. (62).
FC functional class; NYHANew York Heart Association; PHV prosthetic
eart valve.
able 6. Complications of Thrombolytic Therapy of Prosthetic
alve Thrombosis in 107 Patients
Complication n (%)
eripheral emboli 4 (3.7)
entral nervous system bleeding 2 (1.9)
troke 3 (2.8)
ransient ischemic attack 3 (2.8)
oronary emboli 3 (2.8)
leeding requiring transfusion 4 (3.7)
eath 6 (5.6)
ll embolic complications 15 (14.0)
ny complication 19 (17.8)rom Tong AT et al. (62).
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Year in Valvular Heart Disease January 4, 2005:111–22onography, counts of high-intensity transient signals in 39
atients with obstructed PHV were 8.3 10.8 versus 2.2
.4 (p  0.0002) in patients with normal PHV function
67).
coring system for prediction of risks for thromboembo-
ism (TE). A total of 370 patients (249 AVR, 93 MVR, 28
VR) were studied prospectively with a mean follow-up of
.4 years (maximum 6.6). On multivariate analysis, 13
ndependent predictors for TE were identified. The authors
tated, “These risk factors were additive when present in the
ame patient, enabled a scoring system to be developed that
ccurately predicted risk of TE based on number of risk
actors” (68).
hort- and long-term impact of valve prosthesis-patient
ismatch (VP-PM). SHORT-TERM INCREASED MORTAL-
TY WITH SEVERE VP-PM. Thirty-day mortality was assessed
n 1,266 consecutive patients undergoing AVR (69). In
hose with “severe” VP-PM (AVA 0.65 cm2/m2), the
ortality was 7 of 27 patients (25.9%); with “moderate”
AVA 0.85 cm2/m2) and “mild” VP-PM (AVA 0.85
m2/m2) the mortality was 27 of 447 (6.0%) and 23/769
3.0%), respectively. Patients with severe VP-PM compared
ith moderate VP-PM had a much higher incidence of
omen, coronary artery disease, hypertension, diabetes,
mergency/salvage operation, and concomitant coronary
rtery bypass graft surgery. The risk ratio for mortality for
evere versus moderate was 7.2 (95% confidence interval of
.5 to 20.9).
In analysis of predictors of mortality, the authors have
ombined the moderate and severe subgroups.
Comment: Although the body surface area of those in the
evere VP-PM was larger than in those in the moderate and
ild subgroups, a very much higher percentage of these
atients received PHV size 21 mm (77.8% in the severe
roup vs. 31.1% in the moderate group and 9.5% in the mild
roup). There was no separate analysis of risk predictors in
nly the subgroup of severe VP-PM, and thus, one cannot
e certain whether co-morbid conditions, rather than severe
P-PM, were the major causes of the increased mortality.
n this regard, small prosthesis size (21 mm) was an
mportant predictor of operative mortality for AVR in
ritically ill patients (70). It is not possible clinically to
alculate valve area with any degree of precision to hun-
redths of a centimeter, and thus, severe VP-PM should be
0.6 cm2/m2, moderate 0.6 cm2 to 0.9 cm2/m2, and
ild should be 0.9 cm2/m2 (58).
ATE RESULTS OF VP-PM: INCREASED HF AND HF DEATHS.
n a study of 1,563 patients undergoing AVR with
ollow-up of 4.3  3.3 years (range 60 days to 17.1 years)
71), the adjusted hazard ratio (95% confidence interval) at
ve years for HF with mismatch (0.75 cm2/m2) was 1.64
1.01 to 2.56), p 0.047, and for HF deaths was 2.09 (1.03
o 4.27), p  0.043. 2eprint requests and correspondence: Dr. Shahbudin H.
ahimtoola, Distinguished Professor, University of Southern
alifornia, 2025 Zonal Avenue, Los Angeles, California 90033.
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